Adenoviruses are currently used in a variety of bench and bedside applications. However, their employment in gene delivery to lymphocyte lineages is hampered by the lack of coxsackie virus and adenovirus receptor (CAR) on the cell surface. Exploitation of an alternative receptor on the surface of T lymphocytes can allow for utilization of adenovirus in a variety of T lymphocyte-based diseases and therapies. Here, we describe how resistance to infection can be overcome by the utilization of a bi-specific fusion protein, soluble CAR murine interleukin 2 (sCAR-mIL-2), that retargets adenovirus to the murine IL-2 receptor (IL-2R). Infection of a murine T-cell line, CTLL-2, with a sCAR-mIL-2/Adenovirus conjugate provided a ninefold increase in both green fluorescence protein-positive cells and luciferase expression. In addition, this increase in infection was also seen in isolated primary murine T lymphocytes. In this context, the sCAR-mIL-2 adapter provided a fourfold gene transduction increase in activated primary murine T lymphocytes. Our results show that recombinant sCAR-mIL-2 fusion protein promotes IL-2R-targeted gene transfer to murine T lymphocytes and that alternative targeting can abrogate their native resistance to infection.
INTRODUCTION
The utilization of genetically modified T lymphocytes has gained much attention in treating a variety of disorders, including autoimmune disorders, cancer, infectious disease and transplant rejection. [1] [2] [3] Current vector strategies rely upon lentivirus and retrovirus vectors for genetic delivery. These strategies, however, are hampered by a variety of vector-related issues. Ineffective transduction, 4 low viral titers, and their reliance upon host cellcycle progression 5 all impede the full utilization of these vectors. In addition, such vectors raise biosafety concerns such as the occurrence of insertional oncogenesis 6, 7 and disregulation 8 due to vector integration. In principle, adenoviruses type 5-based vectors (Ad5) retain many properties that could be utilized in genetically modifying T cells. However, full utilization is confounded biologically by the lack of coxsackie virus and adenovirus receptor (CAR) expression in T cells. 9, 10 To surmount CAR deficiency, multiple strategies have been endeavored to reroute adenoviral into non-CAR pathways. Most of these strategies have included genetically modifying Ad5 to retarget new cellular receptors, such as CD46 and avb3 and avb5 integrins. [11] [12] [13] [14] [15] In addition, strategies involving the use of adapter molecules like bi-specific antibody conjugates against CD3 16 and the use of non-genetic methods of transduction using lipofectamine 17 have been endeavored. However, the gains from these approaches have not achieved practical levels of utility.
With this in mind, we endeavored to reroute adenovirus into a CAR-independent pathway that would provide enhanced transduction of T lymphocytes. Of the possible T lymphocyte-specific targets, interleukin 2 receptor (IL-2R) represented a potentially useful candidate. As an Ad5-retargeting receptor, IL-2R is T lymphocyte specific and highly expressed in therapeutic T lymphocyte populations such as CD4 þ Foxp3 þ regulatory T lymphocytes and activated CD4 þ and CD8 þ T lymphocytes. 18 Here, we explored a novel strategy utilizing a bi-specific protein/adapter composed of soluble CAR fused to murine interleukin 2 (mIL-2) to target adenovirus to murine T lymphocytes. We show that this adapter remains biologically active and does not lose its binding potential to IL-2R. More importantly, this adapter promotes improved levels of gene transduction in both murine T-cell cultures and primary murine T lymphocytes. These data indicate that alternative targeting strategies to T lymphocytes can yield enhanced levels of gene delivery and, as such, Ad5 may be a novel tool in T lymphocyte-based treatments of disease.
(Sigma-Aldrich, St Louis, MO, USA) containing 10% fetal bovine serum (FBS) (Hyclone, Logan, UT, USA), 2 mM L-glutamine, 100 U ml À 1 penicillin and 100 mg ml À 1 streptomycin (Mediatech, Manassas, VA, USA). CTLL-2 cells were cultured in RPMI 1640 (Invitrogen) containing 10% FBS, 100 U ml À 1 penicillin, 100 mg ml À 1 streptomycin, 50 mg ml À 1 betamercaptoethanol and 10 U ml À 1 recombinant human IL-2 (eBioscience, San Diego, CA, USA). All cells were propagated at 37 1C in a 5% CO 2 atmosphere. The cell lines infected with the Ad5 vectors were maintained using the corresponding cell culture medium but containing 2% instead of 10% FBS.
Primary T lymphocytes
Primary T lymphocytes were isolated from the harvested spleens of C57BL/6J mice. A single-cell suspension of splenocytes was made by straining cells through a 70-mm nylon mesh screen. Primary T lymphocytes were then isolated by magnetic beads (Pan T Cell Isolation Kit II, Miltenyi Biotec, Auburn, CA, USA) according to the manufacturer's directions. Isolated primary T lymphocytes were then immediately used for infection studies or incubated using a T-Cell Activation/Expansion Kit (Miltenyi Biotec).
Construction of recombinant adenovirus plasmids
Ad5GL plasmid, encoding an adenovirus expressing both green fluorescence protein (GFP) and firefly luciferase under cytomegalovirus (CMV) promoters, was constructed as previously described. 20 The adenovirus shuttle plasmid, pSH-UP-UP-GFP (R), 21 contains an ubiquitin c promoter (UP) driving expression of GFP and a second UP with a multiple cloning site downstream. This plasmid was then digested with NotI and the larger fragment re-ligated, creating a shuttle plasmid with only one UP driving GFP, pShUP-GFP.
Adenoviral vectors
The recombinant adenoviral plasmids were linearized by PacI digested and transfected into HEK293 cells using Lipofectamine 2000 reagent (Invitrogen). All vectors propagated in HEK293 cells were purified by two rounds of CsCl gradient ultracentrifugation. 22 CsCl was removed by dialysis against phosphate-buffered saline (PBS; pH 7.4) containing 10% glycerol. The Ad5 vectors were stored at À 80 1C before use. The infectious titer (plaque-forming units (pfu) ml À 1 ) of purified Ad5 vectors was determined by triplicate TCID 50 assays using HEK293A cells, as described elsewhere. 22 The physical titer (viral particles (vp) ml À 1 ) were determined by Maizel's method with a conversion factor of 1.1 Â 10 12 vp ml À 1 per absorbance unit at 260 nm. 23 
Lentiviral vectors
The lentiviral vector used in the study to obtain purified sCAR-mIL-2 was constructed as described previously. 24 The resulting lentiviral vector contained an internal myeloproliferative sarcoma virus enhancer with the negative control region-deleted promoter (MND) 25 expressing sCAR-mIL-2 (the ectodomain of human CAR fused to mIL-2 via a short, six-histidine (6HIS) tag containing peptide linker). sCAR-mIL-2 is fused to puromycin N-acetyl-tranferase gene via an internal ribosomal entry site 26 and is followed by the central polypurine tract/central termination sequence. The virus was generated as described by Zielske and Gerson. 24 Briefly, HEK293T cells were triple transfected with the packaging vector (pCMVdeltaR8.91), the VSV-G pseudotyping vector (pMD.G) and the pLVmnd-sCAR-mIL-2 transfer vector at a mass ratio of 3:1:3, using Lipofectamine 2000 reagent according to the manufacturer's instructions. Virus produced 24-48 h after transfection was harvested in Dulbecco's Modified Eagle Medium (SigmaAldrich) containing 10% FBS and 2 mM L-glutamine. Virus-enriched media was filtered through 0.45 mm syringe filter units (Millipore, Billerica, MA, USA) and stored at À 80 1C.
Production of stable sCAR-mIL-2 expressing cells HEK293 cells were infected with the lentivirus, LVmnd-sCAR-mIL-2. Following infection, the cells were distributed in a 96-well plate and grown in medium supplemented with 3 mg ml À 1 puromycin until about 2/3 of the well surface was covered. The supernatants from the wells were then tested for sCAR-mIL-2 production by dot-blot assay using rabbit antibodies against CAR produced in the laboratory. A sCAR-mIL-2 expressing clone was expanded for future analysis.
Purification of the sCAR-mIL-2 adapter protein
The medium from stable sCAR-mIL-2-expressing cells was collected and proteins precipitated by addition of an equal volume of cold-saturated ammonium sulfate (Sigma-Aldrich). Following centrifugation, the precipitate was dissolved in 1/20 the original volume of PBS and then dialyzed against PBS. The sCAR-mIL-2 protein was then purified from the dialyzed solution by immobilized metal-affinity chromatography using cobaltimmobilized TALON affinity resin (Clontech, Mountain View, CA, USA) followed by dialysis against PBS.
Western blot analysis of sCAR-mIL-2
Aliquots of purified sCAR-mIL-2 equal to 500 ng were denatured by boiling in laemmli sample buffer (Bio-Rad Laboratories, Hercules, CA, USA) at 95 1C for 10 min. The protein concentration was determined using the DC protein assay kit (Bio-Rad Laboratories) according to the manufacturer's instructions. The proteins were separated by electrophoresis in sodium dodecyl sulfate 10% polyacrylamide gels. The separated viral proteins were transferred onto a polyvinylidene difluoride membrane. Subsequently, western blot analysis was performed using a rat monoclonal anti-mIL-2 antibody S4B6 (BD Biosciences, San Jose, CA, USA) or rabbit polyclonal anti-CAR antibody followed by a horseradish peroxidase-conjugated secondary anti-mouse or anti-rabbit antibody (Dako North America, Carpinteria, CA, USA). The blot was developed using an ECL Plus Western Blotting Detection Kit (Amersham Biosciences, Pittsburgh, PA, USA). Pre-stained protein ladder of Kaleidoscope Standards (Bio-Rad Laboratories) was used in the stained gel and the western blot.
Enzyme-linked immunosorbent (ELISA) assay
The binding specificity of the sCAR-mIL-2 adapter protein to the Ad5 recombinant knob 27 was tested by ELISA. Recombinant Ad5 fiber knob or BSA was diluted in 0.2 M sodium carbonate/bicarbonate buffer, absorbed in triplicate on a 96-well plate at 300 ng per well and incubated at 4 1C overnight. The plate was then washed three times in wash buffer (0.1 M phosphate, 0.15 M sodium chloride, pH7.2 containing 0.05% Tween 20) and incubated in blocking buffer (5% non-fat milk in wash buffer) at 4 1C overnight. Blocking buffer was then removed, twofold dilutions of sCARmIL-2 was added and incubated for 1 h at room temperature. Following incubation, the plate was washed three times, rabbit polyclonal anti-CAR antibody added and incubated for 1 h at room temperature. Plate was then washed three times, anti-rabbit-HRP (Bio-Rad Laboratories) added and incubated at room temperature for 1 h. Following this incubation, the plate was washed six times, Sigma Fast o-phenylenediamine dihydrochloride substrate (Sigma-Aldrich) added and developed according to manufacturer's directions. Absorbance was measured at 492 nm.
In vitro proliferation assay
We performed in vitro proliferation assays using CTLL-2 cells as previously described.
28,29 CTLL-2 cells were plated in flat-bottomed 96-well tissue culture plates at 1 Â 10 4 cells per well in quadruplicate. Varying concentrations of either purified sCAR-mIL-2 or recombinant mIL-2 (eBioscience) were added to each well and incubated at 37 1C in a 5% CO 2 atmosphere for 48 h. Ten microliters of water-soluble tetrazolium-1 reagent (Clontech) was added to each well and incubated for 4 h. Plates were then read at an absorbance 450 nm, with a reference wavelength of 690 nm according to manufacturer's instructions.
In vitro proliferation blocking assays were performed in a similar fashion to the proliferation assays previously described with rat monoclonal antimurine CD25 antibody PC61 (BD Biosciences) or rat monoclonal immunoglobulin G (IgG) control antibody (BD Biosciences) added 30 min before the addition of sCAR-mIL-2. Cells were then incubated with 28 ng ml À 1 of sCAR-mIL-2, a concentration that gave roughly 85% maximum proliferation.
Gene transfer assays CTLL-2 or primary murine T cells were distributed at a density of 5 Â 10 5 cells per well in a 24-well plate. Indicated amounts of sCAR-mIL-2 were incubated with 2.5 Â 10 8 vp (500 vp per cell) of Ad5GL (CTLL-2 cells) or Ad5UP-GFP (primary murine T lymphocytes) for 30 min at 37 1C. The sCAR-mIL-2/Ad5 complexes were then transferred to the cells and incubated for 1 h at 37 1C followed by virus removal and medium change to growth medium supplemented with recombinant human IL-2 to control for proliferation differences between infected and non-infected cells.
Twenty-four (CTLL-2 cells) or forty-eight (primary murine T lymphocytes) hours post infection, the cells were measured for luc and/or GFP expression.
Flow cytometry
Expression of CAR and CD25 on CTLL-2 cells were analyzed by flow cytometry. CTLL-2 cells were stained for CAR using an anti-CAR antibody RmcB conjugated to biotin. Cells were then incubated with streptavidin labeled with Alexa Flour 647 (Invitrogen). A mouse IgG-biotin (Invitrogen) followed by streptavidin-Alexa Flour 647 and streptavidin-Alexa Flour 647 alone was used as isotype controls. CTLL-2 cells were stained for CD25 using anti-CD25 PC61 conjugated to allophycocyanin (APC; BD Biosciences). Rat IgG1-APC (BD Biosciences) was used as an isotype control.
Mock, Ad5GL and sCAR-mIL-2-conjugated Ad5GL-transduced CTLL-2 cells were tested for GFP expression. Cells were harvested 24 h post infection, washed three times in FACS (fluorescence-activated cell sorter) buffer and analyzed for GFP fluorescence by flow cytometry. Data were represented as percentage of cells expressing GFP protein.
Mock, Ad5UP-GFP and sCAR-mIL-2-conjugated Ad5UP-GFP-transduced naive and activated murine T lymphocytes were tested for CD25 and GFP expression. Cells were harvested 48 h post infection, washed twice with FACS buffer and stained for CD25 using anti-CD25-APC antibody or rat IgG1-APC control for 1 h at 4 1C. Following incubation, the cells were washed three times in FACS buffer, and CD25 and GFP expression were analyzed. Data were represented as percentage of cells positive for CD25 and/or GFP expression.
All data were acquired by flow cytometry using BD FACSAria Special Edition (BD Biosciences) and analyzed by FlowJo software version 10.0.4 (Tree Star, Ashland, OR, USA).
RESULTS

Generation of sCAR-mIL-2 adapter
Previous work has shown that Ad5 is a poor candidate for gene delivery to T cells due mainly to a lack of the Ad5 receptor, CAR. Therefore, retargeting adenovirus to a cell surface protein that is highly expressed, such as the IL-2R, should provide for increased gene transduction. Our lab has previously shown that utilizing a bi-specific protein/adapter allows for efficient retargeting of Ad5. [30] [31] [32] [33] [34] To this end, our laboratory has developed the use of bi-specific fusion proteins that bind adenovirus fiber knob and our target of interest, in this case murine IL-2R. The aim of the current study was to generate a recombinant fusion protein capable of affecting association between the native CAR binding of the Ad5 fiber and IL-2R. We assembled the cDNA coding for the recombinant fusion protein, sCAR-mIL-2 (Figure 1a) , consisting of the ectodomain of human CAR fused to mIL-2 via a short peptide linker, preceded by a 6HIS detection/purification tag. These adapters once conjugated to Ad5 have shown dramatically increased gene delivery to otherwise non-infectable cell types (Figure 1b) .
Characterization of sCAR-mIL-2 adapter
To analyze sCAR-mIL-2, we performed a western blot assay on boiled samples of the purified protein. Probing the membranes with antibodies against CAR and mIL-2 ( Figure 2) showed that all portions of the recombinant protein were detected. The electrophoretic mobility of boiled sCAR-mIL-2 showed a molecular weight of approximately 58 kDa. This is higher than the predicted size of 44.6 kDa but could be explained by glycosylation in mammalian cells, as has been noted previously. 34 Further, we analyzed our sCAR-mIL-2 fusion protein for retention of its individual component-binding characteristics. To verify the sCAR portions binding to Ad5 knob, we performed an ELISA assay. Following immobilization of recombinant Ad5 knob or control protein BSA, varying concentrations of sCAR-mIL-2 were incubated and then probed with an anti-mIL-2 antibody (Figure 3a) . These results show that our sCAR-mIL-2 fusion protein still retains efficient binding to the Ad5 knob. We then examined binding of sCAR-mIL-2 to murine IL-2R using a CTLL-2 cell proliferation assay. Purified sCAR-6HIS (six-histidine) (Lane 2) and recombinant mIL-2 (Lane 4) were used as positive control proteins. Black arrow points to the band that comprises sCAR-mIL-2 CTLL-2 cells are an ideal tool for analyzing interactions between IL-2 and its cognate receptor, IL-2R. These cells express high concentrations of IL-2R and are dependent upon signaling through IL-2R for survival and proliferation. This assay showed strong proliferation of CTLL-2 cells when presented with recombinant mIL-2 and sCAR-mIL-2 ( Figure 3b ). This response was also shown to be blockable following incubation of CTLL-2 cells with an anti-murine CD25 antibody (Figure 3c ). This shows that our sCAR-mIL-2 fusion protein is not inducing proliferation through an alternative receptor but exploiting the target, IL-2R. Together, these results indicate that the sCAR-mIL-2 adapter protein was produced in the correct conformation and retains all Ad5 knob and murine IL-2R-binding affinity.
sCAR-mIL-2 enhancement of Ad5-mediated gene transfer to murine T-cell line We next tested the capacity of sCAR-mIL-2 to target Ad5 vectors to cells expressing murine IL-2R in gene transfer experiments using the murine T-cell line, CTLL-2. These cells were verified for positive expression of CD25 and a lack of CAR expression by flow cytometry (Figure 4) . We incubated Ad5GL vector encoding firefly luciferase and GFP under the CMV promoter with different amounts of sCAR-mIL-2 and then used these complexes to transduce CTLL-2 cells. The sCAR-mIL-2 noticeably augmented GFP expression in transduced CTLL-2 cells (Figure 5a ). Approximately 87% of CTLL-2 cells treated with sCAR-mIL-2-conjugated Ad5GL exhibited green fluorescence as compared with o9% for untargeted Ad5GL as measured by flow cytometry. Secondly, sCAR-mIL-2 enhanced luciferase gene expression in CTLL-2 cells with the Ad5GL vector roughly ninefold when compared with Ad5GL alone (Figure 4b ). These results show that Ad5GL complexed with the sCAR-mIL-2 adapter protein is extremely efficient at transducing murine IL-2R expressing CTLL-2 cells.
sCAR-mIL-2 mediated Ad transduction of primary murine T lymphocytes
To next analyze sCAR-mIL-2-mediated transduction of T lymphocytes, we decided to further analyze our sCAR-mIL-2 adapter in primary murine T lymphocytes, as primary cells are frequently more difficult to infect than cell lines. We harvested primary murine T lymphocytes from the spleens of C57BL/6J mice. Following isolation, we analyzed the ability of sCAR-mIL-2 to augment gene transduction of an Ad5 expressing GFP under the UP, Ad5UP-GFP. Forty-eight hours post infection, 1.4% of CD25-positive T lymphocytes showed GFP expression when infected with sCAR-mIL-2-conjugated Ad5UP-GFP compared with 0.046% with unconjugated Ad5UP-GFP, a 30-fold enrichment in GFP-expressing cells (Figure 6 ). Considering that only a small portion of these cells initially expressed CD25, we decided to analyze the ability of sCAR-mIL-2-mediated transduction in an activated T lymphocyte population. Following activation, we infected these activated murine T lymphocytes as we did their naive counterparts. These cells showed increased percentages of GFP-positive cells following transduction with Ad5UP-GFP (1.20%) or sCAR-mIL-2-conjugated Ad5UP-GFP (5.69%), with sCAR-mIL-2 mediating a fourfold increase in GFP-positive cells (Figure 6 ).
DISCUSSION
Despite promising new therapies utilizing genetically modified T lymphocytes, the tools used to efficiently deliver genes to T lymphocytes have been limited. In this study, we have shown that, through the utilization of an adapter-based targeting strategy, Ad5 can be retargeted to the IL-2R on the cell surface of murine T lymphocytes. This strategy was initially chosen because it allows for a rapid exploration of targeting ligands that are not biologically compatible with adenovirus biology. Most secreted biological ligands are not compatible with adenovirus biology, because they are folded and transported through the Golgi apparatus while adenovirus assembly occurs in the nucleus and cytoplasm. The adapter strategy allows construction of targeting moieties that maintain their binding properties and allow for retargeting of adenovirus after conjugation. 35 Initial testing and analysis of our sCAR-mIL-2 adapter was performed in CTLL-2 murine T-cell lines. This cell line was initially chosen, because it is a gold standard for studying IL-2 interactions with its cognate receptor. This cell line, under stimulation from IL-2 signaling, proliferates in a dose-dependent manner. 36, 37 As such, we could utilize this cell line to analyze how binding to IL-2 was affected in our sCAR-mIL-2 adapter. This experiment showed that sCAR-mIL-2 adapter was still effective in stimulating CTLL-2 proliferation (Figure 3b ) and was IL-2R specific (Figure 3c) . Interestingly, our data showed that when molecular weight was taken into consideration, our sCAR-mIL-2 adapter stimulated CTLL-2 cells just as effectively as recombinant mIL-2. These results regarding binding efficiency of sCAR-mIL-2 show that the adapter-based strategy for retargeting adenovirus is amenable to cytokine-based targeting.
The CTLL-2 cell line was also an ideal cell line for initial analysis of sCAR-mIL-2-mediated adenovirus transduction. The cell line showed no expression of CAR on its surface but showed very high levels of expression of CD25, a subunit of the high-affinity IL-2R (Figure 4) . Corresponding with this receptor expression, sCAR-mIL-2 mediated a roughly 10-fold increase in GFP-expressing cells. Of note, both the luciferase and GFP expression reduce slightly at higher concentrations of sCAR-mIL-2. This could be due to saturation of available Ad5 fiber-binding sites, and thus excess sCAR-mIL-2 would compete with virus for available mIL-2R sites on the cell surface.
Following the encouraging results in CTLL-2 cells, we studied the ability of sCAR-mIL-2 adapter to mediate Ad5 gene transduction in primary murine T lymphocytes. An important difference at this stage was the utilization of a UP 21 in place of the CMV promoter analyzed in our CTLL-2 data. Wan 38 and Hurez et al. 10 have both shown that within primary T cells CMV promoter expression is dependent on the activation status of the cell. We felt that this artifact may limit or inhibit our ability to analyze gene expression in primary T lymphocytes. For this reason, we used the UP, which both of these groups have shown to provide good gene expression in both naive and activated T lymphocytes. Following primary T lymphocyte isolation from C57BL/6J mice, we transduced naive cells with adenovirus Ad5UP-GFP utilizing the same protocol developed for CTLL-2 cells. This experiment showed a modest increase of GFP-expressing cells (1.6%) compared with Ad5UP-GFP alone (0.043%). Considering that small percentage of these T lymphocytes expressed CD25 before transduction, we were fairly optimistic with regards to this outcome. To increase our potential pool of targets, we activated isolated primary murine T lymphocytes. Under these conditions, our sCAR-mIL-2 adapter showed a modest 4.6-fold increase in the percentage of GFP-positive CD25-positive T lymphocytes. Previous studies have also shown success in improving gene transduction in primary T lymphocytes. Wickham et al. 16 showed that specifically targeting T cells was possible through the use of a chemically conjugated bi-specific antibody against CD3. This strategy allowed for increased transduction of Jurkat, Molt-3 and resting human T cells. Yotnda et al. 13 applied a panel of fibermodified adenoviruses, including type 5, type 11, type 35, RGD and varying poly-lysine chains, to a variety of human T-cell lines. They showed that many of these non-CAR-targeting moieties can increase adenovirus-delivered GFP expression. They further showed that Ad5/35 could be utilized to infect Epstein-Barr virus-specific cytotoxic T cells with a transduction efficiency of roughly 51-58% as measured by GFP expression. 39 Schroers 12 has also shown that Ad5/35 can be utilized for increased transduction of Jurkat and PM-1 cell lines and primary CD3 positive T cells. Most recently, Sengupta et al. 15 utilized an Ad5 targeted to cell surface integrins through incorporation of an RGD motif into Ad5 fiber knob. Their study showed a threefold increase in luciferase gene transfer and a 2.6-fold increase in hexon in ex vivo infected primary mouse T lymphocytes.
A variety of issues could be hampering gene transduction efficiency of our sCAR-mIL-2-adapter strategy and leading to the variation seen between the initial CTLL-2 model and our later primary murine T lymphocyte data. Colin 40 showed that adenovirus type 5 may have post-internalization defects in HSB-2 T-cell line. These defects lead to normal levels of infection but drastically lower levels of gene transduction, as the Ad5 was unable to escape the endosomal compartment. They hypothesized that the virus was being internalized through an alternative, clathrin-independent method and that the virus was not able to promote escape in this pathway. Interestingly, IL-2 has been shown to internalize in a clathrin-independent method as well. 41 It is a possibility that our sCAR-mIL-2-conjugated Ad5 vector is being internalized through the IL-2Rs pathway instead of through the virus's native pathway that utilizes integrin binding. It may be that this alternative internalization is not amenable to endosomal escape. If this indeed is the case, then alternative T lymphocyte targets may abrogate this issue. Alternative to post-internalization pathways, it may be possible to increase the transduction efficiency through modification of our sCAR-mIL-2 adapter. We have previously shown that the utilization of a trimerization domain within the adapter allows for increased binding of the adapter with adenovirus and leads to further increases in gene transfer. 32, 34, 42 This study along with other recent studies analyzing adenovirus transduction of T lymphocytes show that although native human adenovirus is lacking transduction affinity, alternative targeting strategies can bypass this roadblock. We have demonstrated that new recombinant sCAR-mIL-2 fusion protein promotes IL-2R-targeted gene transfer to murine T lymphocytes. These findings have broad application for the study of T-cell biology and genetic modification of T cells for therapeutic use.
